Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that has been primarily investigated for its potential in cancer therapy. It works by blocking the activity of MMP enzymes, which are involved in tumor invasion, angiogenesis, and metastasis. By inhibiting these enzymes, Marimastat aims to prevent the breakdown of the extracellular matrix, thereby limiting the ability of cancer cells to spread. It has been evaluated in clinical trials for various cancers, including pancreatic, ovarian, and non-small cell lung cancer. Though it showed promise in preclinical studies, clinical results have been mixed, with limited survival benefits and issues related to dose-limiting musculoskeletal toxicity. Beyond oncology, Marimastat has also been explored for use in other conditions involving tissue remodeling, such as arthritis and cardiovascular diseases, due to its ability to modulate MMP activity. However, its development has largely stalled due to efficacy and safety concerns.